Amphastar Pharmaceuticals (AMPH) Free Cash Flow (2013 - 2026)

Amphastar Pharmaceuticals' Free Cash Flow history runs 14 years deep, the most recent figure standing at $43.7 million for Q1 2026.

• On a quarterly basis, Free Cash Flow rose 56.74% year-over-year to $43.7 million in Q1 2026; TTM through Mar 2026 was $137.0 million, a 10.84% decrease from a year earlier, with the FY2025 full-year figure at $121.2 million, down 29.66% from the prior year.
• Free Cash Flow rose to $43.7 million in Q1 2026 per AMPH's latest filing, from $24.6 million in the prior quarter.
• Across five years, Free Cash Flow topped out at $71.2 million in Q2 2024 and bottomed at -$6.9 million in Q4 2024.
• The 5-year median for Free Cash Flow is $36.8 million (2025), against an average of $35.3 million.
• Across the five-year window, Free Cash Flow jumped 1879.94% in 2023 and tumbled 114.33% in 2024, its largest moves.
• Year by year, Free Cash Flow stood at $13.4 million in 2022, then jumped by 259.18% to $48.1 million in 2023, then tumbled by 114.33% to -$6.9 million in 2024, then soared by 456.55% to $24.6 million in 2025, then soared by 77.57% to $43.7 million in 2026.
• Per Business Quant, the three latest AMPH Free Cash Flow figures stand at $43.7 million (Q1 2026), $24.6 million (Q4 2025), and $32.0 million (Q3 2025).